Latest Beta amyloid Stories
Highlights include additional analyses from Phase 3 and ongoing open-label studies, discovery research on the potential use of combination therapy and data on the impact of beta-amyloid imaging on
A specific preparation of cocoa-extract called Lavado may reduce damage to nerve pathways seen in Alzheimer’s disease patients’ brains long before they develop symptoms
- Preclinical data demonstrates reduction of Alzheimer's brain deficits to lower toxic Amyloid-beta and restored synaptic loss - PLANTATION, Fla., May 28, 2014 /PRNewswire/ -- Neurotrope,
MetLife Foundation has announced the recipients of the 2014 MetLife Foundation Awards for Medical Research: Riqiang Yan, Ph.D., vice chair of the Department of Neurosciences, Lerner Research
PITTSBURGH, May 21, 2014 /PRNewswire/ -- Cognition Therapeutics Inc.
A molecular compound developed by Saint Louis University scientists restored learning, memory and appropriate behavior in a mouse model of Alzheimer's disease.
Data Highlight Physician and Payer Expectations for New Symptomatic and Disease-Modifying Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., April 30, 2014 /PRNewswire/
Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.
--Research Published in the Journal of Molecular Biology-- CAMBRIDGE, Mass., April 22, 2014 /PRNewswire/ -- Researchers from NeuroPhage
A team of researchers from Columbia University Medical Center (CUMC), Weill Cornell Medical College, and Brandeis University has devised a wholly new approach to the treatment of Alzheimer's disease involving the so-called retromer protein complex.
- A person who stands up for something, as contrasted to a bystander who remains inactive.
- One of the upright handlebars on a traditional Inuit sled.